EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 783 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC... June 23, 2021 ETV6 Protein Could Be an Important Target for Ewing Sarcoma Treatment March 7, 2023 FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... June 6, 2023 Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... March 14, 2022 Load more HOT NEWS Cleveland Clinic Launches Breast Cancer Vaccine Trial FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL Καρκίνος οισοφάγου New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations...
